The same group performed a phase 3 RCT investigating the efficacy of adjuvant chemo-immunotherapy with AKT-DC, targeting residual micrometastases, in 103 patients with resected NSCLC (67, 68). Here, AKT1 is linked to non-small cell lung carcinoma.